

	Type	L #	Hits	Search Text	DB :	Time Stamp	Comments	Error or Definition	Errors
1	BRS	L1	83	clostridial adj neurotoxin	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 10:52			0
2	BRS	L2	492	botulinum adj (toxin or neurotoxin)	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 10:53			0
3	BRS	L3	11914	lectin	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 10:53			0
4	BRS	L4	401	lectin same (galactose or galactosyl or acetyl galactosamine) same bind\$3	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 10:54			0
5	BRS	L6	2	(1 or 2) same 4	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 10:54			0
6	BRS	L5	10	(1 or 2) same 3	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 11:10			0
7	BRS	L7	127	(erythrina or (glycine adj max) or (arachis adj hypogaea) or (bandeirea adj simplicifolia)) same lectin	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 11:10			0
8	BRS	L8	0	(1 or 2) same 7	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 11:11			0
9	BRS	L9	9210	light adj chain	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 11:11			0
10	BRS	L10	180	translocation adj domain	USPAT; US-PGPUE ; EPO; JPO; DERWENT	2002/11/1 9 11:12			0

	Type	L #	Hits	Search Text	DB :	Time Stamp	Comments	Error or Definition	Errors
11	BRS	L11	6	9 same 10 same (1 or 2)	USPAT; US-PGPUE; EPO; JPO; DERWENT	2002/11/1 9 11:12			0
12	BRS	L12	2	6 same 3	USPAT; US-PGPUE; EPO; JPO; DERWENT	2002/11/1 9 11:13			0
13	BRS	L13	39709 7	control\$4 same (transmission or pain)	USPAT; US-PGPUE; EPO; JPO; DERWENT	2002/11/1 9 11:15			0
14	BRS	L14	0	6 same 13	USPAT; US-PGPUE; EPO; JPO; DERWENT	2002/11/1 9 11:15			0

> d his

(FILE 'HOME' ENTERED AT 11:17:28 ON 19 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA'
ENTERED AT

11:18:01 ON 19 NOV 2002

L1 881 S CLOSTRIDIAL NEUROTOXIN
L2 19773 S (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN)
L3 20134 S L1 OR L2
L4 145857 S LECTIN
L5 9696 S L4 (P) (GALACTOSE OR GALACTOSYL OR
ACETYL GALACTOSAMINE) (P)
L6 1 S L3 (P) L5
L7 48 S L3 (P) L4
L8 26 DUPLICATE REMOVE L7 (22 DUPLICATES REMOVED)
L9 15675 S L4 (P) (GALACTOSE OR GALACTOSYL OR
ACETYL GALACTOSAMINE)
L10 1 S L9 (P) L3
L11 6 S L8 (P) (CONJUGATE OR COVALENT?)
L12 5 S L11 NOT L6
L13 88211 S LIGHT CHAIN
L14 433 S TRANSLOCATION DOMAIN
L15 4 S L3 (P) L13 (P) L14
L16 0 S L15 (P) L4

=> log y

FILE 'HOME' ENTERED AT 11:17:28 ON 19 NOV 2002

=> file medline caplus biosis embase scisearch agricola		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 11:18:01 ON 19 NOV 2002

FILE 'CAPLUS' ENTERED AT 11:18:01 ON 19 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 11:18:01 ON 19 NOV 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 11:18:01 ON 19 NOV 2002
COPYRIGHT (C) 2002 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 11:18:01 ON 19 NOV 2002
COPYRIGHT (C) 2002 Institute for Scientific Information (ISI) (R)

FILE 'AGRICOLA' ENTERED AT 11:18:01 ON 19 NOV 2002

=> s clostridial neurotoxin
L1 881 CLOSTRIDIAL NEUROTOXIN

=> s (botulinum toxin) or (botulinum neurotoxin)
L2 19773 (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN)

=> s l1 or l2
L3 20134 L1 OR L2

=> s lectin
L4 145857 LECTIN

=> s l4 (p) (galactose or galactosyl or acetylgalactosamine) (p) bind?
L5 9696 L4 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE) (P)
BIND?

=> s l3 (p) l5
L6 1 L3 (P) L5

=> d l6 1 ibib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:249106 CAPLUS
DOCUMENT NUMBER: 130:276767
TITLE: Conjugates of ***galactose*** - ***binding***
lectins and ***clostridial***
neurotoxins as analgesics
INVENTOR(S): Duggan, Michael John; Chaddock, John Andrew
PATENT ASSIGNEE(S): The Speywood Laboratory Limited, UK; Microbiological
Research Authority
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9917806	A1	19990415	WO 1998-GB3001	19981007
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,				

MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2306350 AA 19990415 CA 1998-2306350 19981007
AU 9893574 A1 19990427 AU 1998-93574 19981007
AU 741456 B2 20011129
ZA 9809138 A 19990527 ZA 1998-9138 19981007
EP 996468 A1 20000503 EP 1998-946571 19981007

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI

JP 2001518522 T2 20011016 JP 2000-514674 19981007

PRIORITY APPLN. INFO.:

GB 1997-21189 A 19971008

WO 1998-GB3001 W 19981007

AB A class of novel agents that are able to modify nociceptive afferent
function is provided. The agents may inhibit the release of
neurotransmitters from discrete populations of neurons and thereby reduce
or preferably prevent the transmission of afferent pain signals from
peripheral to central pain fibers. They comprise a ***galactose*** -
binding ***lectin*** linked to a deriv. of a
clostridial ***neurotoxin***. The deriv. of the
clostridial ***neurotoxin*** comprises the L-chain, or a
fragment thereof, which includes the active proteolytic enzyme domain of
the light (L) chain, linked to a mol. or domain with membrane-
translocating activity. The agents may be used in or as pharmaceuticals
for the treatment of pain, particularly chronic pain.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:17:28 ON 19 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
11:18:01 ON 19 NOV 2002

L1 881 S CLOSTRIDIAL NEUROTOXIN
L2 19773 S (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN)
L3 20134 S L1 OR L2
L4 145857 S LECTIN
L5 9696 S L4 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE) (P)
L6 1 S L3 (P) L5

-- s 13 (P) L4

L7 48 L3 (P) L4

=> duplicate remove l7

DUPLICATE PREFERENCE IS 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L7

L8 26 DUPLICATE REMOVE L7 (22 DUPLICATES REMOVED)

=> s L4 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE)

L9 15675 L4 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE)

=> s 19 (p) l3

L10 1 L9 (P) L3

=> s l8 (p) (conjugate or covalent?)

PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH

FIELD CODE - 'AND' OPERATOR ASSUMED 'L75 (P) '

L11 6 L8 (P) (CONJUGATE OR COVALENT?)

=> s_l11 not_l6

L12 5 L11 NOT L6

=> d l12 1-5 ibib abs

L12 ANSWER 1 OF 5 MEDLINE

ACCESSION NUMBER: 2002470902 MEDLINE

DOCUMENT NUMBER: 22218001 PubMed ID: 12105193

TITLE: Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel ***conjugate*** a Clostridium ***botulinum*** ***toxin*** A endopeptidase fragment and Erythrina cristagalli ***lectin*** .

AUTHOR: Duggan Michael J; Quinn Conrad P; Chaddock John A; Purkiss John R; Alexander Frances C G; Doward Sarah; Fooks Sarah J; Friis Lorna M; Hall Yper H J; Kirby Elizabeth R; Leeds Nicola; Mouldsdaile Hilary J; Dickenson Anthony; Green G Mark; Rahman Wahida; Suzuki Rie; Shone Clifford C; Foster Keith A

CORPORATE SOURCE: Centre for Applied Microbiology and Research, Porton Down, Salisbury, Wiltshire SP4 0JG, United Kingdom.

SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (2002 Sep 20) 277 (38) 34846-52.
Journal code: 2985121R. ISSN: 0021-9258.

PUB. COUNTRY: United States

DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)

LANGUAGE: English

FILE SEGMENT: Priority Journals

ENTRY MONTH: 200210

ENTRY DATE: Entered STN: 20020917
Last Updated on STN: 20021026
Entered Medline: 20021024

AB ***Clostridial*** ***neurotoxins*** potently and specifically inhibit neurotransmitter release in defined cell types. Here we report that a catalytically active derivative (termed LH(N)/A) of the type A neurotoxin from Clostridium botulinum has been coupled to a ***lectin*** obtained from Erythrina cristagalli to form a novel ***conjugate*** . This ***conjugate*** exhibits an in vitro selectivity for nociceptive afferents compared with the anatomically adjacent spinal neurons, as assessed using in vitro primary neuronal culture systems to measure inhibition of release of neurotransmitters. Chemical ***conjugates*** prepared between E. cristagalli ***lectin*** and either natively sourced LH(N)/A or recombinant LH(N)/A purified from Escherichia coli are assessed, and equivalence of the recombinant material are demonstrated. Furthermore, the dependence of inhibition of neurotransmitter release on the cleavage of SNAP-25 is demonstrated through the use of an endopeptidase-deficient LH(N)/A ***conjugate*** variant. The duration of action of inhibition of neurotransmitter released by the ***conjugate*** in vitro is assessed and is comparable with that observed with Clostridium ***botulinum*** ***neurotoxin*** . Finally, in vivo electrophysiology shows that these in vitro actions have biological relevance in that sensory transmission from nociceptive afferents through the spinal cord is significantly attenuated. These data demonstrate that the potent endopeptidase activity of ***clostridial*** ***neurotoxins*** can be selectively retargeted to cells of interest and that inhibition of release of neurotransmitters from a neuronal population of therapeutic relevance to the treatment of pain can be achieved.

L12 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2001:228744 CAPLUS

DOCUMENT NUMBER: 134:247267

TITLE: Clostridial neurotoxin targeted conjugates for inhibition of secretion from non-neuronal cells

INVENTOR(S): Foster, Keith Alan; Chaddock, John Andrew; Purkiss, John Robert; Quinn, Conrad Padraig

PATENT ASSIGNEE(S): Microbiological Research Authority, UK

SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021213	A2	20010329	WO 2000-GB3669	20000925
WO 2001021213	A3	20020711		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1235594 A2 20020904 EP 2000-962721 20000925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL

PRIORITY APPLN. INFO.: GB 1999-22554 A 19990923
WO 2000-GB3669 W 20000925

AB A method of treatment of disease by inhibition of cellular secretory processes is provided. The method has particular application in the treatment of diseases dependent on the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system, and bone cells. Agents and compns. therefor, as well as methods for manufg. these agents and compns., are provided. In a preferred embodiment a clostridial neurotoxin, substantially devoid of holotoxin binding affinity for neuronal cells of the presynaptic muscular junction, is assocd. with a targeting moiety. The targeting moiety is selected such that the clostridial toxin conjugate so formed may be directed to a non-neuronal target cell to which the conjugate may bind. Following binding, a neurotoxin component of the conjugate, which is capable of inhibition of cellular secretion, passes into the cytosol of the target cell by cellular internalization mechanisms. Thereafter, inhibition of secretion from the target cell is effected.

L12 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:706999 CAPLUS

DOCUMENT NUMBER: 133:261538

TITLE: Use of a lectin or lectin conjugate for modulation of C-fiber activity, and therapeutic use thereof

INVENTOR(S): Foster, Keith Alan; Chaddock, John Andrew; Quinn, Conrad Padraig

PATENT ASSIGNEE(S): Microbiological Research Authority, UK

SOURCE: PCT Int. Appl., 62 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000057897	A1	20001005	WO 2000-GB1247	20000331
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1165114	A1	20020102	EP 2000-914295	20000331
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

PRIORITY APPLN. INFO.: GB 1999-7429 A 19990331
WO 2000-GB1247 W 20000331

AB The invention relates to the treatment of pain and to compds. that modulate C-fiber activity. In particular, the invention relates to the use of a ***lectin*** in the manuf. of a medicament for modulation of C-fiber neuron activity, and to ***lectin*** ***conjugates***. The ***lectin*** ***conjugates*** comprise a ***lectin*** coupled to a peptide or protein, wherein the peptide or protein is substantially free of ***Clostridial*** ***neurotoxin*** enzyme activity. The invention also concerns methods for manufg. the ***conjugates***. The compds. and compns. described have particular application in the treatment of diseases of which C-fiber activity is a component. Such diseases include pain, inflammation, psoriasis and other C-fiber related conditions.

REFERENCE COUNT:

5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER: 2000:144760 CAPLUS

DOCUMENT NUMBER: 132:175838

TITLE: Compounds inhibiting exocytosis in mucus-secreting
cells or neurotransmitter release from neurons that
control or direct mucus secretion for treatment of
mucus hypersecretionINVENTOR(S): Quinn, Conrad Padraig; Foster, Keith Alan; Chaddock,
John Andrew

PATENT ASSIGNEE(S): Microbiological Research Authority, UK

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000010598	A2	20000302	WO 1999-GB2806	19990825
WO 2000010598	A3	20000615		
W: AU, CA, JP, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2341429	AA	20000302	CA 1999-2341429	19990825
AU 9955250	A1	20000314	AU 1999-55250	19990825
EP 1107794	A2	20010620	EP 1999-941754	19990825
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002523377	T2	20020730	JP 2000-565918	19990825
PRIORITY APPLN. INFO.:			GB 1998-18548	A 19980825
			WO 1999-GB2806	W 19990825

AB A method of treating mucus hypersecretion, the causative factor in chronic obstructive pulmonary disease (COPD), asthma, and other clin. conditions involving COPD, comprises administering a compd. that inhibits exocytosis in mucus secreting cells or neurons that control or direct mucus secretion. Also described is a compd., for use in the treatment of hypersecretion of mucus, which inhibits mucus secretion by inhibiting mucus secretion by mucus secreting cells, and/or inhibiting neurotransmitter release from neuronal cells controlling or directing mucus secretion.

L12 ANSWER 5 OF 5 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 2002:520037 BIOSIS

DOCUMENT NUMBER: PREV200200520037

TITLE: Characterisation of a novel ***conjugate*** of a
botulinum ***neurotoxin*** A endopeptidase
fragment and E. cristagalli ***lectin***AUTHOR(S): Ling, R. J. (1); Fretwell, R.; Alexander, F.; Fooks, S.;
Leeds, N.; Jameson, K.; Hall, Y.; Kirby, E.; Chaddock, J.;
Shone, C.CORPORATE SOURCE: (1) Centre for Applied Microbiology and Research, Porton
Down, Salisbury, Wiltshire, SP4 0JG UKSOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology, (June,
2002) Vol. 365, No. Supplement 2, pp. R28. print.
Meeting Info.: International Conference on Basic and
Therapeutic Aspects of Botulinum and Tetanus Toxins
Hannover, Germany June 08-12, 2002
ISSN: 0028-1298.

DOCUMENT TYPE: Conference

LANGUAGE: English

=> d his

(FILE 'HOME' ENTERED AT 11:17:28 ON 19 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT
11:18:01 ON 19 NOV 2002

L1 881 S CLOSTRIDIAL NEUROTOXIN
 L2 19773 S (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN)
 L3 20134 S L1 OR L2
 L4 145857 S LECTIN
 L5 9696 S L4 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE) (P)
 L6 1 S L3 (P) L5
 L7 48 S L3 (P) L4
 L8 26 DUPLICATE REMOVE L7 (22 DUPLICATES REMOVED)
 L9 15675 S L4 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE)
 L10 1 S L9 (P) L3
 L11 6 S L8 (P) (CONJUGATE OR COVALENT?)
 L12 5 S L11 NOT L6

=> s light chain

L13 88211 LIGHT CHAIN

=> s translocation domain

L14 433 TRANSLOCATION DOMAIN

=> s l3 (p) l13 (p) l14

L15 4 L3 (P) L13 (P) L14

=> s l15 (p) l4

L16 0 L15 (P) L4

=> d his

(FILE 'HOME' ENTERED AT 11:17:28 ON 19 NOV 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, SCISEARCH, AGRICOLA' ENTERED AT 11:18:01 ON 19 NOV 2002

L1 881 S CLOSTRIDIAL NEUROTOXIN
 L2 19773 S (BOTULINUM TOXIN) OR (BOTULINUM NEUROTOXIN)
 L3 20134 S L1 OR L2
 L4 145857 S LECTIN
 L5 9696 S L4 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE) (P)
 L6 1 S L3 (P) L5
 L7 48 S L3 (P) L4
 L8 26 DUPLICATE REMOVE L7 (22 DUPLICATES REMOVED)
 L9 15675 S L4 (P) (GALACTOSE OR GALACTOSYL OR ACETYLGALACTOSAMINE)
 L10 1 S L9 (P) L3
 L11 6 S L8 (P) (CONJUGATE OR COVALENT?)
 L12 5 S L11 NOT L6
 L13 88211 S LIGHT CHAIN
 L14 433 S TRANSLOCATION DOMAIN
 L15 4 S L3 (P) L13 (P) L14
 L16 0 S L15 (P) L4

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	52.85	53.06
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.48	-2.48

STN INTERNATIONAL LOGOFF AT 11:25:19 ON 19 NOV 2002